PSM retrospective 1,620 hospitalized patients in the USA, 84 with existing famotidine use, showing lower risk of combined death/intubation with treatment.
|
risk of death/intubation, 57.0% lower, RR 0.43, p = 0.02, treatment 8 of 84 (9.5%), control 332 of 1,536 (21.6%), NNT 8.3, propensity score matching.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Freedberg et al., 21 May 2020, retrospective, propensity score matching, USA, peer-reviewed, 15 authors.
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study
MD, MS Daniel E Freedberg, Joseph Conigliaro, Timothy C Wang, Kevin J Tracey, Michael V Callahan, MD, MS Julian A Abrams, Magdalena E Sobieszczyk, David D Markowitz, Aakriti Gupta, Max R O’donnell, Jianhua Li, David A Tuveson, Zhezhen Jin, William C Turner, Donald W Landry
Gastroenterology, doi:10.1053/j.gastro.2020.05.053
See Covering the Cover synopsis on page 803.
Supplementary Material Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at https://doi.org/10.1053/ j.gastro.2020.05.053.
References
Anand, Ziebuhr, Wadhwani, None, Science
Bourinbaiar, Fruhstorfer, None, Life Sci
Chen, Deng, Churchill, None, Cell Stem Cell
Gottschlich, Delegge, Guenter, American Society for Parenteral and Enteral Nutrition
Li, Zhang, Liu, Gu, None, FASEB J
Wu, Liu, Yang, None, Acta Pharm Sin B
